Health Care Technology
Company Overview of IBM Watson Health
IBM Watson Health operates a cloud-based data sharing hub that includes clinical, research, and social data from various health sources. It offers its solutions for doctors, researchers, and insurers. IBM Watson Health has a strategic alliance with Siemens Healthineers. The company was founded in 2015 and is headquartered in Armonk, New York. IBM Watson Health operates as a subsidiary of International Business Machines Corporation.
1 New Orchard Road
Armonk, NY 10504
Founded in 2015
Key Executives for IBM Watson Health
IBM Watson Health does not have any Key Executives recorded.
IBM Watson Health Key Developments
IDx and IBM Watson Health Forge Alliance for Eye Health
Mar 17 17
IBM Watson Health and IDx, LLC announced a five-year strategic alliance to advance eye health through cognitive computing applications. The alliance aims to help primary care providers, hospitals, health systems, and integrated delivery networks deliver value-based care to patients with diabetic retinopathy and other serious eye conditions such as glaucoma and age-related macular degeneration. The alliance expands IBM Watson Health's focus on eye health. The alliance leverages more than a decade of IDx's ophthalmic image analysis work and IBM's cognitive healthcare offerings and global reach. As part of the alliance, IBM Watson Health has the option to distribute IDx offerings. Initially, IBM Watson Health intends to distribute IDx-DR -- an automated solution for diabetic retinopathy screening currently available in the 31 countries that comprise the European Economic Area. IBM Watson Health may expand its distribution of IDx-DR to Australia, Canada, and the United States upon regulatory approvals of the product.
Munich Leukemia Laboratory Enters into Co-development Agreement with IBM Watson Health and Illumina
Mar 9 17
Munich Leukemia Laboratory GmbH has entered into an co-development agreement with IBM Watson Health and Illumina, Inc. to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment. Pursuant to the agreement, Munich Leukemia Laboratory will use NovaSeq technology from Illumina, to sequence samples from its biobank of more than 500,000 cases. Munich Leukemia Laboratory researchers then plan to use IBM Watson to help analyze the genomic data alongside other data sources. The project intends to include innovative testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNA-Seq) in 5,000 cases. Following successful development, the tool could also be made available to other laboratories in the future. As part of the agreement, Munich Leukemia Laboratory will utilize Illumina’s BaseSpace Informatics Suite to be able to streamline data analysis, storage, data curation and aggregation. The BaseSpace Sequence Hub Frankfurt site will help Munich Leukemia Laboratory manage the data as the project scales and facilitates data transfer to IBM Watson. Additional tertiary analysis with BaseSpace Cohort Analyzer and BaseSpace Correlation Engine allows Munich Leukemia Laborator’s genomic data to be combined with other clinical data to enhance interpretation results. This agreement enables Munich Leukemia Laboratory, IBM Watson Health and Illumina to create and implement new cognitive approaches to data-driven challenges for health systems that are increasingly overwhelmed by data. This agreement enables Munich Leukemia Laboratory, IBM Watson Health and Illumina to create and implement new cognitive approaches to data-driven challenges for health systems that are increasingly overwhelmed by data.
IBM, Watson Health and Central New York Care Collaborative Announce Agreement
Feb 20 17
IBM, Watson Health and the Central New York Care Collaborative (CNYCC) have announced an agreement to create a cognitive population health platform intended to connect more than 2,000 healthcare and community based providers across six counties in Central New York. The platform will be designed to help improve health for residents across the region, with the goal to reduce costs in the Medicaid system by decreasing the amount of avoidable emergency department visits and hospital readmissions by 25% over the course of the program. The population health platform will integrate IBM Watson Care Manager with broader Watson Health offerings and run on the Watson Health Cloud. The untapped value of insights from health industry data is estimated to be near $300 billion annually. Patient data often resides in multiple siloes, preventing physicians from understanding the full spectrum of health issues that could impact a patients care and potential risk factors. For example, an endocrinologist may be unaware that her diabetes patient also suffers from depression, which significantly impacts the risk of non-adherence. For CNYCCs Population Health Management (PHM) System, IBM Watson Health will integrate data from a variety of care settings -- primary care, post-acute care, behavioral health, community and acute care and more than 75 electronic health record systems, health information exchanges, and other data sources. CNYCCs PHM system will aggregate that diverse data and produce holistic patient insights incorporating clinical history, social determinants, and behavioral health. Clinicians can access information about their individual patients from the platform, and opt to connect with a patient to prompt adoption of healthy behaviors relevant to office visits and care management; for example, send a private reminder to pick up a prescription.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|